3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
3
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Lung Carcinoma Metastatic in the Brain
1
Kidney Neoplasms
1
Glioblastoma
1
Cranial Nerve Diseases
1
Chondrosarcoma
1
Central Nervous System Neoplasms
1
Bone Neoplasms
1
Interventions
Filgrastim
4
Ifosfamide
3
Carboplatin
3
Peripheral Blood Stem Cell Transplantation
2
Immune Checkpoint Inhibitors
2
Etoposide
2
spartalizumab
1
regorafenib
1
perifosine
1
pegfilgrastim
1
pazopanib
1
ivosidenib
1
etoposide phosphate
1
enasidenib
1
drozitumab
1
angiotensin I (1-7)
1
alanosine
1
abemaciclib
1
Vincristine
1
Trabectedin
1
Topotecan
1
Thiotepa
1
Sunitinib
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Radiotherapy, Conformal
1
Radiotherapy
1
Radiosurgery
1
Proton Therapy
1
Pharmacogenomic Testing
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Chondrosarcoma
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts